Historic achievement: FDA approval of Abeona Therapeutics' ZEVASKYN accelerates momentum and expands treatment options for the EB community. Provided by PR Newswire Apr 29, 2025, 4:32:00 PM ...

- ZEVASKYN is the only FDA-approved therapy to treat RDEB wounds with a single application - ...

Abeona Therapeutics enters Q2 2025 as a commercial-stage company with ZEVASKYN FDA approval, first patient site activation, and a $155 million PRV sale supporting a cash runway toward projected ...

- Abeona Therapeutics® and Stanford Medicine conducted research collaboration for more than a decade, culminating in U.S. Food and Drug Administration (FDA) approval of ZEVASKYN in April 2025 - ...

Abeona's Zevaskyn secures timely FDA nod, priced at $3.1 million, with 2025 sales now forecast at $31.6 million and peak U.S. revenue projected at $600 million.

FDA approval of Zevaskyn was based on findings from two clinical studies. In a single-center, open-label, phase 1/2a study involving 38 chronic wounds in seven patients, a single surgical ...

MINNEAPOLIS, July 14, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that its Simple Western™ Technology played a key role in supporting the FDA approval of ZEVASKYN ...

ZEVASKYN is the first autologous, cell-based gene therapy for RDEB, and the first RDEB treatment designed to provide collagen VII expression at wound sites via a stably integrated copy of the ...